US Stock Insider Trading | Xeris Biopharma Disclosed Two Insider Trading Transactions on March 16

K-LinePoet · 2026-03-17T00:11:01+00:00

On March 16, 2026, Xeris Biopharma disclosed that executive McCulloch Kevin purchased 48,900 shares on March 12. Additionally, other executives have recently engaged in multiple buy and sell transactions, demonstrating active investment activity within the company. Xeris Biopharma specializes in the biopharmaceutical industry, committed to improving patients' lives.

K-LinePoet

2026-03-17 00:11:01

Abstract generation in progress

On March 16, 2026, Xeris Biopharma (XERS) disclosed two insider trading transactions. Executive Kevin McCulloch purchased 48,900 shares on March 12, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 16, 2026	Executive	Kevin McCulloch	March 12, 2026	Buy	4	3.94	15.76
March 16, 2026	Executive	Kevin McCulloch	March 12, 2026	Buy	48,900	4.09	200,000
March 5, 2026	Executive	Steven Pieper	March 5, 2026	Buy	14,000	5.93	83,200
March 5, 2026	Executive	Steven Pieper	March 5, 2026	Buy	27,900	4.09	114,100
March 4, 2026	Executive	Beth Hecht	March 2, 2026	Sell	16,600	6.24	103,400
March 4, 2026	Executive	Beth Hecht	March 2, 2026	Sell	100	7.06	706.00
February 25, 2026	Executive	Anh Tu Nguyen	February 24, 2026	Sell	29,300	6.88	201,600
February 2, 2026	Executive	Kevin McCulloch	January 31, 2026	Sell	126,100	7.36	927,800
February 2, 2026	Executive	Steven Pieper	January 31, 2026	Sell	205,500	7.36	1,512,700
February 2, 2026	Director	John Patrick Shannon Jr.	January 31, 2026	Sell	340,500	7.36	2,506,100

[Company Profile]

Xeris Biopharma Holdings, Inc. was incorporated in Delaware in 2005. The company is dedicated to building an innovative, self-sustaining, growth-oriented biopharmaceutical company focused on improving patients’ lives by developing and commercializing a range of clinically meaningful therapies. The company has a unique advantage through three commercial products and proprietary formulation science (XeriSol and XeriJect) to achieve this goal, establishing partnerships and enhancing candidate products.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes